MS4A1 Monoclonal Antibody

說明書

中文名稱：

MS4A1鼠單克隆抗體
貨號：

CSB-MA000204
規(guī)格：

￥1090
圖片：
IHC staining of Human tonsil tissue paraffin-embedded, diluted at 1:200.
其他：

產(chǎn)品詳情
產(chǎn)品評價
相關(guān)產(chǎn)品
靶點詳情

產(chǎn)品詳情

產(chǎn)品描述：

CUSABIO貨號：CSB-MA000204 MS4A1單克隆抗體靶向B細胞表面標志物CD20蛋白（由MS4A1基因編碼），該跨膜蛋白特異性表達于B淋巴細胞發(fā)育階段，通過調(diào)節(jié)鈣離子通道參與B細胞活化與增殖，是免疫調(diào)控及血液腫瘤研究的重要生物標志物。本產(chǎn)品采用雜交瘤技術(shù)制備，經(jīng)ELISA和免疫組織化學（IHC）嚴格驗證，具備高特異性識別能力，適用于人源、小鼠及大鼠多種實驗體系的B細胞檢測。在基礎(chǔ)科研領(lǐng)域廣泛應(yīng)用于B淋巴細胞發(fā)育分化研究、非霍奇金淋巴瘤發(fā)病機制探索、自身免疫疾病免疫調(diào)節(jié)機制分析，以及抗CD20治療藥物的靶點驗證實驗，為腫瘤免疫治療、免疫缺陷疾病研究提供優(yōu)質(zhì)試劑支持。該抗體具有批間穩(wěn)定性優(yōu)異、種屬兼容性廣的特點，特別適合多模型比較研究，是探究B細胞生物學功能及免疫微環(huán)境調(diào)控的關(guān)鍵工具。
Uniprot No.：

P11836
基因名：

MS4A1
別名：

MS4A1; CD20; B-lymphocyte antigen CD20; B-lymphocyte surface antigen B1; Bp35; Leukocyte surface antigen Leu-16; Membrane-spanning 4-domains subfamily A member 1; CD antigen CD20
宿主：

Mouse
反應(yīng)種屬：

Human,Mouse,Rat
免疫原：

Synthetic Peptide
免疫原種屬：

H, M, R
標記方式：

Non-conjugated
抗體亞型：

IgG
克隆號：

10B1
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

PBS, pH 7.4, containing 0.02% sodium azide as Preservative and 50% Glycerol.
產(chǎn)品提供形式：

Liquid
應(yīng)用范圍：

ELISA,IHC

推薦稀釋比：

Application	Recommended Dilution
IHC	1:100-1:200

Protocols：

ELISA Protocol
Immunohistochemistry (IHC) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評價

靶點詳情

功能：

B-lymphocyte-specific membrane protein that plays a role in the regulation of cellular calcium influx necessary for the development, differentiation, and activation of B-lymphocytes. Functions as a store-operated calcium (SOC) channel component promoting calcium influx after activation by the B-cell receptor/BCR.
基因功能參考文獻：
1. Our study found that a small subset of papillary thyroid carcinomas (<10%, mainly of classic variant) exhibited aberrant membranous expression of CD20 PMID: 29079175
2. Our results support the fact that CD200 can be added to routine Chronic lymphoproliferative disorders panel as it is useful in subcategorizing them. However, inclusion of CD20 ABC to routine panel does not seem plausible but may be done for difficult diagnostic cases or where anti-CD20 therapy is planned. PMID: 29567884
3. showed here that 3' UTR NOTCH1 mutations are associated with low CD20 expression and with relative resistance to anti-CD20 immunotherapy in vitro PMID: 28550186
4. We conclude that the relationship between complement-regulatory proteins CFHR1 and CFHR3 and response to anti-CD20 mAb therapy varies based on the specific anti-CD20 mAb used. PMID: 27528699
5. Limiting the antibody-induced induction of immunosuppressive reactive oxygen species may improve the anti-leukemic efficacy of anti-CD20 therapy in chronic lymphocytic leukemia. PMID: 27097113
6. Case Report: primary cutaneous T-cell lymphoma with aberrant CD20 expression. PMID: 27840885
7. Data suggest that insulitis (destruction of pancreatic beta-cells and their ability to produce/secrete insulin) occurs in two distinct profiles in type 1 diabetes; these differ in proportion of CD20-positive B-lymphocytes (relative to CD4-positive T-lymphocytes) present within the infiltrate; greater infiltration of CD20-positive B-lymphocytes leads to more aggressive disease progression. PMID: 26858360
8. PZ-DHA also arrested MDA-MB-231 cell division at the G2/M phase and down-regulated expression of cyclin B1 and cyclin-dependent kinase 1 (CDK1) PMID: 27535497
9. there is a high CD23a/CD23b ratio of chronic lymphocytic leukemia cells, which demonstrates that in a subset of CLL cases, low CD23 expression together with high CD20 and CD38 expressions may serve as a surrogate for trisomy 12 PMID: 26119874
10. IL-17-producing pathogenic T lymphocytes co-express CD20 in primary Sjogren's syndrome patients. PMID: 26814615
11. Studies indicate that CD20 antigen expression is absent in a variety of diffuse large B cell lymphomas (DLBCLs), including plasmablastic lymphoma, primary effusion lymphoma, anaplastic lymphoma, kinase-positive DLBCL, and large B cell lymphoma arising in human herpesvirus 8-associated multicentric Castleman disease. PMID: 26459310
12. lipid formulations based on a polyplex or lipoplex backbone additionally equipped with anti-CD20 antibodies are promising non-viral vectors for specific oligonucleotide transfer into human tumor cells. PMID: 26585505
13. The ABC values obtained for CD20 expression levels using PE, APC, or PerCP Cy5.5 are consistent over the five different instrument platforms for any given apparently healthy donor independent of the fluorochrome used PMID: 26013593
14. Data indicate that Philadelphia chromosome-positive (Ph-positive) acute lymphoblastic leukemia (ALL) patients who presented with cyclin dependent kinase inhibitor 2A/B (CDKN2A/B) deletion showed a higher rate of CD20 antigen expression. PMID: 27090891
15. the findings demonstrate that treatment with anti-CD20-hIFNalpha reverses resistance of B-NHL PMID: 26398317
16. Case Report: aberrant CD20 expression by skin-infiltrating T cells using multispectral imaging. PMID: 26381030
17. Microenvironment CD20 + cells seem to play a favorable prognostic role in classical Hodgkin Lymphoma. Depletion of CD20 + cells together with an increase of TAMs identifies a group of patients with high-risk disease. PMID: 25098425
18. In conclusion, SNPs of CD20 were not high risk factors of DLBCL, but the T allele of rs2070770 was a potential indicator of superior survival. PMID: 24898664
19. Characterize premature human NK/T-cell lymphoma cell line with expression of the B-cell marker CD20. PMID: 26299072
20. Data indicate that CD20 antigen downregulation relies on transcriptional mechanisms in SRC family kinases (SFKs)-dependent transcriptional regulation of CD20. PMID: 25517315
21. This study identified a novel D393-CD20-derived MHC Class II restricted epitopes that bind various HLA-DR alleles. IFN-gamma-producing D393-CD20 specific CD4 T cell responses were detected in blood lymphocytes from lymphoma patients and D393-CD20 specific CD4 Th1 clones were able to recognize both lymphoma cell lines and autologous lymphoma cells and to induce their apoptosis. PMID: 25449106
22. Letter/Review: Liver transplant recipients developing CD20-positive lymphoproliferative lesions are significantly older at time of transplantation. PMID: 25394454
23. CD20 in multiple myeloma without the t(11;14) may have a role in poor prognosis and aberrant expression of Wnt signaling PMID: 24408089
24. in two cases of mycosis fungoides, CD20 was expressed by a significant population of the neoplastic T-cells, but these T-cells lacked expression of other B-cell markers, including CD79a, CD19 and PAX5. PMID: 24467775
25. Data indicate that depletion of CD20-expressing T cells may also contribute to the therapeutic effect of rituximab (RTX). PMID: 24928997
26. Significantly lower rates of CD20 B cells were found in women with placental malaria infections compared with those without such infections. Neither placental malaria infection nor CD20 are associated with low birth weight. PMID: 24245949
27. Expansion aggregation of CD20+ B cells, HLA-DR expression and arteriolar hyaline thickening influence the outcome of acute cellular rejection in renal allograft. PMID: 23428174
28. Patients whose percentage of CD20 antigen was above 60.3% had longer treatment-free survival. PMID: 23659384
29. CD20 protein was aberrantly expressed in T-mycosis fungoides lesions PMID: 24145652
30. MS4A1/CD20 is responsible for TGF-beta-induced apoptosis of B-cell lymphoma cells. Moreover, downregulation of MS4A1/CD20 by TGF-beta attenuated the effects of the monoclonal anti-MS4A1/CD20 antibody, rituximab, on Ramos cells. PMID: 22665052
31. Anti-hCD20 IgE antibodies have in vitro cytotoxic activity. PMID: 22692757
32. Case Report: CD20-positive NK/T-cell lymphoma with an indolent clinical course. PMID: 23031227
33. CD20 antigen is not expressed in cancer stem cells in multiple myeloma. PMID: 22315496
34. CD20 expression in B-cell precursor acute lymphoblastic leukemia is common in Mexican patients and lacks a prognostic value. PMID: 22664043
35. Data indicate that the bridging of CD20 antigen and FcgammaRIIIa is an essential interaction for the initiation of antibody dependent cell-mediated cytotoxicity (ADCC) activity and assay. PMID: 22914441
36. CD20-positive posttransplant lymphoproliferative disorder lesions in kidney transplant patients are significantly more likely to develop early after transplant and represent an inferior outcome. PMID: 22758374
37. Data show that in the blood of rheumatoid arthritis (RA) patients, a greater proportion of Th17 cells are of a CD20+ phenotype compared to healthy individuals, suggesting these cells may represent an additional target for anti-CD20 therapies. PMID: 22171710
38. Prenyltransferases regulate CD20 protein levels and influence anti-CD20 monoclonal antibody-mediated activation of complement-dependent cytotoxicity PMID: 22843692
39. Dsta show that differential expression of MS4A1 is a stromal signal of uncertain significance, and an example of the rationale for tumor cell enrichment in preparation for gene expression studies to identify markers of particular tumor phenotypes. PMID: 22514692
40. Report disappointing results after long term treatment of lupus nephritis with anti-CD20 antibody rituximab. PMID: 21258801
41. B-cell depletion induces transient aggressive behavior in BDC2.5 diabetogenic T cells and reduction in regulatory T (Treg) cell number and function during the B-cell depletion period. PMID: 22490442
42. Defects in CD20/ B-cell receptors signalosome conformation might predispose to the spectrum of common variable immunodeficiency disorders. PMID: 22130422
43. Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50. PMID: 22517865
44. Results suggest for the clinical utility of CD20-specific T cells in B cell malignancies. PMID: 21630262
45. Case Report: obtained good results in 2 high-titer ABO-incompatible living donor kidney transplantation using anti-CD20 and anti-CD25 antibodies without splenectomy, in conjunction with a calcineurin inhibitor plus mycophenolate mofetil or mizoribine. PMID: 21839272
46. Using protein tomography, different CD20 complexes were found to be associated with the 2 antibodies, and confocal microscopy showed different membrane compartmentalization of these subpopulations of the cellular CD20 pool. PMID: 21444918
47. The neoplastic epithelial cells in cases of type A and type AB thymoma, as well as few cases of type B1 and B2 thymoma, express CD20. PMID: 21092589
48. Adoptively T cells transduced anti-CD20scFvFc/CD28/CD3zeta gene mediates enhanced anti-tumor activities against CD20 positive tumor cells, suggesting a potential of gene-based immunotherapy for non-Hodgkin lymphoma. PMID: 20815894
49. Quantification of CD20 mRNA and protein levels in chronic lymphocytic leukemia suggests a post-transcriptional defect. PMID: 20674973
50. CD20 immunoexpresion in early rheumatoid arthritis synovium. PMID: 20191119
顯示更多

收起更多
相關(guān)疾?。?/div>
Immunodeficiency, common variable, 5 (CVID5)
亞細胞定位：

Cell membrane; Multi-pass membrane protein. Cell membrane; Lipid-anchor.
蛋白家族：

MS4A family
組織特異性：

Expressed on B-cells.
數(shù)據(jù)庫鏈接：

HGNC: 7315

OMIM: 112210

KEGG: hsa:931

STRING: 9606.ENSP00000314620

UniGene: Hs.712553

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
VIM Recombinant Monoclonal Antibody

Applications: ELISA, IHC, IF

Species Reactivity: Human
VDR Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human